ACRS at a glance
Aclaris Therapeutics, Inc. (ACRS, SEC CIK 1557746) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and Form 4 insider filings as recently as August 4, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Aclaris Therapeutics, Inc. (ACRS) reported revenue of $7.8 million (down 58.2% from FY2024) and a net loss of $64.9 million. Diluted EPS was -$0.53.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Aclaris Therapeutics, Inc. (ACRS) shares worth $152.1 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $7.8M
- −58.2% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $152.1M · +1 vs prior quarter
- Latest 8-K
- Aug 6, 2026
- Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- No profitability, margin, or net-income percentages provided in the excerpt
- Forward-looking statements subject to risks and uncertainties; no specific outlook or updated guidance disclosed in the excerpt
Risk Factors
- No risk-factors section provided; submitted text contains only trading-arrangement disclosures, exhibits, and signatures
- No newly added or materially updated risk identified in the provided excerpt
AI summary of the ACRS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 1.01: Entry into a Material Definitive Agreement
- Amended ATM enables discretionary common-stock sales through Leerink and Cantor under Form S-3 registration
- Prior agreement authorized up to $100.0 million of common-stock sales
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 contains only filing-incorporation language, with no operating results or financial metrics
- Investors must rely on the referenced exhibit or accompanying earnings release for fiscal 2026 results
Item EX-99.1: Item EX-99.1
- Q2 net loss widened to $21.5M from $15.4M as R&D rose to $18.1M, reflecting accelerated ATI-052 development
- Cash, equivalents and marketable securities reached $170.6M; subsequent ATM sales added $40.2M from 7.3M shares
Item 5.07: Submission of Matters to a Vote of Security Holders
- 80.55% shareholder participation, with 112,499,671 of 139,663,680 shares represented
- Anand Mehra and Maxine Gowen elected directors through 2029
AI summaries of ACRS 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ACRS
Don't miss the next ACRS filing
- Alerts as it files. A push when ACRS files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ACRS, by share count.
- Ask anything. An AI agent that reads every ACRS filing and answers with sources.
ACRS alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Kolbeck Roland Wilhelm | M | Aug 1, 2026 | 36,375 | - |
| Kolbeck Roland Wilhelm | F | Aug 1, 2026 | 12,385 | $5.20 |
| Kolbeck Roland Wilhelm | M | Aug 1, 2026 | 36,375 | - |
| GOWEN MAXINE | M | Jun 5, 2026 | 11,580 | - |
| SCHIFF ANDREW N | M | Jun 5, 2026 | 11,580 | - |
| Mehra Anand | M | Jun 5, 2026 | 11,580 | - |
| Humphries William D. | M | Jun 5, 2026 | 11,580 | - |
| MILANO VINCENT | M | Jun 5, 2026 | 11,580 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $18.7M | $7.8M |
| Operating Income | - | -$141.9M | -$76.4M |
| Net Income | -$88.5M | -$132.1M | -$64.9M |
| Op. Margin | - | -758.2% | -975.9% |
| Net Margin | - | -705.5% | -829.6% |
| Balance Sheet | |||
| Total Assets | $197.4M | $220.3M | $160.5M |
| Equity | - | $155.6M | $103.1M |
| ROE | - | -84.9% | -63.0% |
| Per Share | |||
| EPS | $-1.27 | $-1.71 | $-0.53 |
| Cash Flow | |||
| Operating CF | - | -$20.1M | -$47.1M |
| CapEx | $1.3M | $121K | $111K |
Source: XBRL data in Aclaris Therapeutics, Inc. (ACRS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ACRS share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $152.1M |
| Q1 2026 | 26 | $102.4M |
| Q4 2025 | 24 | $87.6M |
| Q3 2025 | 24 | $57.7M |
| Q2 2025 | 22 | $42.4M |
| Q1 2025 | 19 | $31.3M |
| Q4 2024 | 14 | $31.6M |
| Q3 2024 | 10 | $10.9M |
- BlackRock+2.63M (+36%)
- State Street Corp+1.25M (+62%)
- Vanguard Capital Management LLC+650.4K (+13%)
- Renaissance Technologies LLC+314.9K (+63%)
- Northern Trust+270.5K (+37%)
- Morgan Stanley−2.61M (-95%)
- Citadel Advisors LLC−487.2K (-22%)
- D.E. Shaw & Co−486.3K (-54%)
- Two Sigma Investments−262.6K (-66%)
- Millennium Management−232.2K (-31%)
- Mangrove Partners+50.3K
Source: 13F-HR filings on SEC EDGAR (aggregated from 166 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ACRS filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Sep 21, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 4, 2026 | - | - | - |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 4 | Jun 8, 2026 | - | - | |
| 8-K | Jun 4, 2026 | - | Analysis | |
| 10-Q | May 7, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 7, 2026 | - | Analysis | |
| 4 | May 5, 2026 | - | - | - |
| 8-K | Apr 28, 2026 | - | Analysis | - |
| 4 | Apr 27, 2026 | - | - | - |
| SC 13G | Apr 7, 2026 | - | - | |
| SC 13G | Mar 17, 2026 | - | - | |
| 8-K | Mar 11, 2026 | - | Analysis | - |
| 8-K | Mar 10, 2026 | - | Analysis | - |
| 4 | Mar 3, 2026 | - | - | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 4 | Feb 6, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
- ACET · Adicet Bio IncPharmaceutical Preparations
ACRS SEC filings: frequently asked questions
Which institutions hold ACRS stock?
As of June 30, 2026, the largest Aclaris Therapeutics, Inc. (ACRS) holders among the 13F filers tracked by SignalX were BlackRock ($53.1 million), Vanguard Capital Management LLC ($30.8 million), State Street Corp ($17.2 million), Citadel Advisors LLC ($9.3 million), Vanguard Portfolio Management LLC ($7.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ACRS's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Aclaris Therapeutics, Inc. (ACRS) reported revenue of $7.8 million (down 58.2% from FY2024) and a net loss of $64.9 million. Diluted EPS was -$0.53. The figures come from the XBRL data in the 10-K.
What did ACRS report in its latest 8-K?
Aclaris Therapeutics, Inc. (ACRS) filed an 8-K on August 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement). Amended ATM enables discretionary common-stock sales through Leerink and Cantor under Form S-3 registration.
What are the latest ACRS SEC filings?
Aclaris Therapeutics, Inc. (ACRS) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on August 6, 2026 and a Form 4 insider filing on August 4, 2026.
What is ACRS's SEC CIK number?
Aclaris Therapeutics, Inc. (ACRS)'s SEC Central Index Key (CIK) is 1557746. EDGAR lists every ACRS filing under that number.
Ask anything about ACRS
The research agent reads ACRS's filings, financials, insider trades and 13F holders, then answers with sources.